VM 301

Drug Profile

VM 301

Alternative Names: OAS 1000; Pseudopterosin A methyl ether

Latest Information Update: 27 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OsteoArthritis Sciences
  • Developer Nexell Therapeutics [CEASED]; OsteoArthritis Sciences
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Pseudopterosins
  • Mechanism of Action Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis; Chronic wounds; Inflammation

Most Recent Events

  • 14 Aug 2002 Discontinued - Phase-II for Chronic wounds in USA (Topical)
  • 14 Aug 2002 Discontinued - Preclinical for Atopic dermatitis in USA (Topical)
  • 14 Aug 2002 Discontinued - Preclinical for Inflammation in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top